+++ Embargo: 28 January 2019, 11h00 ET/17h00 CET +++

Finding second hits to knock out leukemia

Targeted drugs are a cornerstone of personalized medicine, yet come with important drawbacks. They restrain disease progression – but rarely eradicate the cancer. Patients therefore need to take the drugs essentially forever, exposing them to severe side effects and incurring high costs for the healthcare system. Combination therapies could potentially overcome these limitations. A study by scientists from CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences in collaboration with the Medical University of Vienna shows how epigenetic analysis and automated microscopy help prioritize new drug combinations for leukemia therapy. The results were published in *Nature Chemical Biology*.

(Vienna, 28 January 2019) Many new anti-cancer drugs inhibit proteins that are essential for the proliferation of cancer cells. One example is ibrutinib, an innovative therapy for chronic lymphocytic leukemia first approved in 2014. Chronic lymphocytic leukemia is caused by uncontrolled growth of cells from the body’s immune system. It is the most common leukemia in the Western world.

Ibrutinib breaks the circle of rampant cell proliferation and allows even patients with high-risk chronic lymphocytic leukemia to survive for many years. However, patients must keep taking the drug every day and endure side effects, often severe, including fever, pain, and fatigue.

To improve the treatment of chronic lymphocytic leukemia toward higher efficacy and fewer side effects, scientists are increasingly exploring combination therapies. Ideally, such drug combinations exploit vulnerabilities that ibrutinib induces in leukemia cells, with the ultimate goal of hitting the leukemia in a hard enough way to later make treatment unnecessary.

To speed up the search for promising drug combinations, a team of scientists at CeMM and the Medical University of Vienna developed a method that can effectively sift through a large number of possibilities and identify those drug combinations that have true potential. The work describing the outcome was published in *Nature Chemical Biology* (DOI: 10.1038/s41589-018-0205-2) on 28 January 2019.

The new approach combines epigenetic analysis using a method called ATAC-seq (pronounced “attack-seq”) with comprehensive testing of single-cell drug sensitivity. This approach identified characteristic epigenetic changes in leukemia cells for patients undergoing ibrutinib treatment. On top, scientists performed high-throughput imaging, by automated confocal microscopy, to identify drug sensitivities that were specific for these leukemia cells and not for healthy cells of the very same patient. All of these
experiments were done on primary samples collected from patients before and during ibrutinib treatment, which enabled a systematic analysis of ibrutinib-induced drug vulnerabilities.

Christoph Bock, Principal Investigator at CeMM and corresponding author of the paper emphasizes the relevance for personalized medicine: “To keep a cancer at bay, it often takes several drugs at the same time. The search for such combination therapies unfortunately involves a lot of trial and error. This is why we have developed a method that predicts and prioritizes what is likely going to work. The first results in chronic lymphocytic leukemia are promising, and I am convinced that our method will help develop personalized therapies for leukemia and other cancers.”

Ulrich Jäger, Professor of Hematology at the Medical University of Vienna and Head of the Clinical Department for Hematology and Haemostaseology at the Vienna General Hospital highlights the medical context of the new method: “Treatment of leukemias with single drugs carries the risk of resistance and failure to respond. A new method to develop combination therapies more systematically indeed constitutes an important advance for cancer research.”

Giulio Superti-Furga, Scientific Director at CeMM and Professor for Medical Systems Biology at the Medical University of Vienna concludes: “The study is a beautiful example for translational medicine and the impact of basic research on clinical praxis. In summary, it provides a powerful method for the rational development of combination therapies and a step toward truly personalized oncology.”

**Attached pictures:** 1. Leukemia cells undergoing drug screening (illustration). Leukemia cells are depicted in green, normal blood cells in red, and the intricate bundles in each cell visualize the complex arrangement of DNA and chromatin in the cell’s nucleus (© Ella Marushchenko). 2. Visualization of the chromatin structure that folds ~2 meters of DNA into the cell’s micrometer-scale nucleus. 3. Scientist at CeMM analyzing epigenetic regulation of leukemia cells (© CeMM).

**The study** “Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL” was published in *Nature Chemical Biology* on 28 January 2019. DOI: 10.1038/s41589-018-0205-2

**Authors:** Christian Schmidl*, Gregory I Vladimer*, André F Rendeiro*, Susanne Schnabl*, Tea Pemovska, Christina Taubert, Thomas Krausgruber, Mohammad Araghi, Nikolaus Krall, Berend Snijder, Rainer Hubmann, Anna Ringler, Kathrin Runngatscher, Dita Demirtas, Oscar Lopez de la Fuente, Martin Hilgarth, Cathrin Skrab, Edit Porpaczy, Michaela Gruber, Gregor Hoermann, Stefan Kubicek, Philipp Staber, Medhat Shehata#, Giulio Superti-Furga#, Ulrich Jäger#, Christoph Bock#.

* Co-first author / These authors contributed equally to this work
# Co-last author / These authors jointly supervised this work
**Funding:** This study was supported by the Austrian Academy of Sciences (OeAW), the Vienna Science and Technology Fund (WWTF), the Austrian Science Fund (FWF), the European Molecular Biology Organisation (EMBO), “Initiative Krebsforschung” of the Medical University of Vienna, the Austrian Society of Hematology and Oncology, the Anniversary Fund of the Austrian National Bank (OeNB), and the European Research Council (ERC).

**CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences** seeks to achieve maximum scientific innovation in molecular medicine to improve healthcare. At CeMM, an international and creative team of scientists and medical doctors pursues free-minded basic life science research in a large and vibrant hospital environment of outstanding medical tradition and practice. CeMM’s research is based on post-genomic technologies and focuses on societally important diseases, such as immune disorders and infections, cancer and metabolic disorders. CeMM operates in a unique mode of super-cooperation, connecting biology with medicine, experiments with computation, discovery with translation, and science with society and the arts. The goal of CeMM is to pioneer the science that nurtures the precise, personalized, predictive and preventive medicine of the future. CeMM trains a modern blend of biomedical scientists and is located at the campus of the General Hospital and the Medical University of Vienna.

[www.cemm.at](http://www.cemm.at)

**The Medical University of Vienna** is one of the most traditional medical education establishments with nearly 8,000 students and approximately 5,500 staff members, and one of the most important top-level biomedical research institutions in Europe. Its international outlook is one of its most important pillars and the research focus is centered on immunology, cancer research, imaging, brain research and cardiovascular diseases.

[https://www.meduniwien.ac.at/web/en](https://www.meduniwien.ac.at/web/en)

For further information please contact:

______________________________
Eva Schweng
Public Relations Manager
______________________________

**CeMM**
Research Center for Molecular Medicine of the Austrian Academy of Sciences
Lazarettgasse 14, AKH BT 25.3
1090 Vienna, Austria
Phone +43-1/40160-70 051
Fax +43-1/40160-970 000
eschweng@cemm.oeaw.ac.at
www.cemm.at